Loading…
Loading…
Structured register of government actions in the geoeconomic space — export controls, tariffs, sanctions, FDI screening, subsidies, industrial-policy laws — cross-referenced into the country, minerals, and ETF surface. Charter: docs/IPTM_CHARTER.md.
Severity 1-5 is the qualitative impact rating (1=minor, 5=structural). The bilateral-trade-grounded quant scorer is the next IPTM milestone. RBI (Register Breadth Index) is a complementary structural-breadth indicator from scripts/py/iptm/breadth.py; divergence between RBI and severity is itself informative (high-sev / low-RBI = strategic chokepoint; low-sev / high-RBI = broad but shallow). Every action has at least one primary source URL. Verify-or-don't-file. See also themes, timeline, graph, sankey, map, country exposure, sector exposure, material exposure (+ graph), weekly briefs, portfolio scan, escalation monitor, trans-shipment hubs. Internal triage tools (RSS-poller candidate feed, source-feed health) live under /admin/candidates + /admin/sources. Subscribe via Atom feed (accepts ?country=CN, ?material=lithium, ?issuer=BIS, ?type=export_control, ?etf=SOXX, ?company=NVDA, ?minSeverity=4, ?year=2026, ?q=…) or pull /api/iptm/actions.
The British Business Bank, the UK government's state-owned economic development bank, announced a GBP 50 million cornerstone commitment to Epidarex Capital's new life sciences fund on 20 January 2026. The fund, Epidarex Capital IV, LP, went on to announce a first close of USD 145 million on 27 January 2026, with the Bank joined by the Strathclyde Pension Fund, the Scottish National Investment Bank, and other family-office and corporate investors. This is the Bank's second cornerstone commitment to an Epidarex fund, following a GBP 50 million stake in Epidarex Capital III UK, LP in 2020.
The British Business Bank, the UK government's state-owned economic development bank, took a GBP 10.5 million (USD 13.9 million) equity stake in EpilepsyGTx, a UCL-spinout gene-therapy company, as part of a USD 33 million Series A financing round announced 10 December 2025. The round also included XGEN Venture and an unnamed global biopharmaceutical company; proceeds fund first-in-human Phase 1/2a trials of EpilepsyGTx's lead gene-therapy candidate EPY201 for focal refractory epilepsy.
The British Business Bank, the UK government's state-owned economic development bank, agreed a GBP 75 million (USD 100 million) cornerstone commitment to SV8 Biotech Fund LP, the new flagship multi-stage therapeutics fund managed by SV Health Investors, announced 8 December 2025. It is the Bank's single largest fund commitment to date, taking its cumulative life-sciences fund commitments above GBP 560 million across 15 funds, which the Bank says have collectively leveraged GBP 3.04 billion of private-sector capital.
The UK Department for Science, Innovation and Technology and the Office for Life Sciences launched the Life Sciences Transformational R&D Investment Fund (TRIF) Pilot, a GBP 50 million (approx. USD 67.4 million) capital grant scheme for large-scale R&D projects in the life sciences sector. Only projects with total costs of at least GBP 100 million qualify, with grants typically covering 10-20% of total project costs. The pilot runs on a rolling-application basis until 31 March 2028 or until funding is exhausted.
The British Business Bank, the UK government's economic development bank, announced an GBP 8 million equity investment into NRG Therapeutics Ltd on 8 September 2025 as part of an oversubscribed GBP 50 million (USD 67 million) Series B financing round. NRG Therapeutics develops small-molecule mitochondrial permeability transition pore (mPTP) inhibitors for neurodegenerative diseases including ALS/MND and Parkinson's. The round was led by SV Health Investors' Dementia Discovery Fund, with participation from M Ventures, Novartis Venture Fund, Criteria Bio Ventures, and existing investors Omega Funds and Brandon Capital; a British Business Bank representative joined NRG's board.
The UK Department for Science, Innovation and Technology signed a grant agreement with BioNTech UK Ltd. providing up to GBP 129 million in government support over 10 years, underpinning BioNTech's planned GBP 1 billion (USD 1.3 billion) investment in UK research and development over the same period. The funding backs two new R&D hubs: a life-sciences research centre in Cambridge (genomics, oncology, structural biology, regenerative medicine) and an AI hub co-located with BioNTech's planned UK headquarters in London, run by its InstaDeep subsidiary. The government frames the deal as one of the largest single-company investments in UK life-sciences history and part of the Oxford-Cambridge Growth Corridor and Plan for Change industrial strategy.